# Virogin Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virogin-biotech

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.virogin.com
- Total disclosed funding: $262M
- Latest round: Series D (Sep 24, 2021)
- Investors on record: 12

## About

Established in 2015 and based in Shenzhen, China and headquarter in Canada, Virogin Biotech Ltd. is a biomedical company that develops anti-cancer oncolytic viruses vaccine and oncolytic virus (OV) therapeutics. In September 2020, new investors DH Investments and China Merchants Capital co-led USD 60 million in series C funding for Virogin Biotech Ltd. New investor Korea Investment Partners, Fortune United Partners, Linden Asset Group and unspecified investors also participated in this round.

The company engages in the sales and production of anti-cancer oncolytic viruses vaccine and oncolytic virus (OV) therapeutics.

In the future, the company will deepen its existing clinical projects, follow-up product pipeline continuous research and development and pre-clinical research, as well as potential strategic cooperation. The company will steadily implement its global clinical development strategy.

## Funding rounds

- Series D, Sep 24, 2021, $120M — Panlin Capital, China Capital Management, Shenzhen Capital Real Estate Fund, China Life Capital, GF Qianhe, Linden Asset Group
- Series D, May 7, 2021, $80M — GP Capital, Panlin Capital, Forebright Capital Management, China Structural Reform Fund Co., Ltd.
- Series C, Sep 21, 2020, $62M — CDH Investments, Korea Investment Partners, China Merchants Capital, Panlin Capital, Linden Asset Group

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series C
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series C
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series C
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series C, Series D
- Linden Asset Group — Series C, Series D
- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series D
- Forebright Capital Management (https://capitalatlas.ai/funds/forebright-capital-management) — Series D
- China Structural Reform Fund Co., Ltd. — Series D
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series D
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series D
- China Life Capital — Series D
- GF Qianhe — Series D